379 related articles for article (PubMed ID: 28063196)
21. Salmon-coloured granules in residual acute myeloid leukaemia with t(8;21)(q22;q22.1); RUNX1-RUNX1T1.
Chen D; Chen W
Br J Haematol; 2021 May; 193(4):691. PubMed ID: 33386742
[No Abstract] [Full Text] [Related]
22. Homoharringtonine, aclarubicin and cytarabine (HAA) regimen as the first course of induction therapy is highly effective for acute myeloid leukemia with t (8;21).
Zhu HH; Jiang H; Jiang Q; Jia JS; Qin YZ; Huang XJ
Leuk Res; 2016 May; 44():40-4. PubMed ID: 26994850
[TBL] [Abstract][Full Text] [Related]
23. Therapy-related acute myeloid leukemia with t(8;21) (q22;q22) shares many features with de novo acute myeloid leukemia with t(8;21)(q22;q22) but does not have a favorable outcome.
Gustafson SA; Lin P; Chen SS; Chen L; Abruzzo LV; Luthra R; Medeiros LJ; Wang SA
Am J Clin Pathol; 2009 May; 131(5):647-55. PubMed ID: 19369623
[TBL] [Abstract][Full Text] [Related]
24. Mutations in the CCND1 and CCND2 genes are frequent events in adult patients with t(8;21)(q22;q22) acute myeloid leukemia.
Eisfeld AK; Kohlschmidt J; Schwind S; Nicolet D; Blachly JS; Orwick S; Shah C; Bainazar M; Kroll KW; Walker CJ; Carroll AJ; Powell BL; Stone RM; Kolitz JE; Baer MR; de la Chapelle A; Mrózek K; Byrd JC; Bloomfield CD
Leukemia; 2017 Jun; 31(6):1278-1285. PubMed ID: 27843138
[TBL] [Abstract][Full Text] [Related]
25. Allogeneic hematopoietic stem cell transplantation can improve the prognosis of high-risk pediatric t(8;21) acute myeloid leukemia in first remission based on MRD-guided treatment.
Hu GH; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
BMC Cancer; 2020 Jun; 20(1):553. PubMed ID: 32539815
[TBL] [Abstract][Full Text] [Related]
26. Poor outcome in a pediatric patient with acute myeloid leukemia associated with a variant t(8;21) and trisomy 6.
Kelly MJ; Meloni-Ehrig AM; Manley PE; Altura RA
Cancer Genet Cytogenet; 2009 Feb; 189(1):48-52. PubMed ID: 19167612
[TBL] [Abstract][Full Text] [Related]
27. Minimal residual disease monitoring in t(8;21) acute myeloid leukemia based on RUNX1-RUNX1T1 fusion quantification on genomic DNA.
Duployez N; Nibourel O; Marceau-Renaut A; Willekens C; Helevaut N; Caillault A; Villenet C; Celli-Lebras K; Boissel N; Jourdan E; Dombret H; Figeac M; Preudhomme C; Renneville A
Am J Hematol; 2014 Jun; 89(6):610-5. PubMed ID: 24616160
[TBL] [Abstract][Full Text] [Related]
28. [Frequency and clinical features of ASXL2 gene mutation in acute myeloid leukemia patients with AML1- ETO fusion gene positive].
Zhao JX; Chen XH; Li JL; Pan J; Tan YH; Xu ZF; Ren FG; Zhang YF; Xu J; Li MQ; Li J; Zhang N; Chang JM; Wang XJ; Wang HW
Zhonghua Xue Ye Xue Za Zhi; 2016 Aug; 37(8):676-81. PubMed ID: 27587249
[TBL] [Abstract][Full Text] [Related]
29. Prognostic Role of Postinduction Minimal Residual Disease and Myeloid Sarcoma Type Extramedullary Involvement in Pediatric RUNX1-RUNX1T1 (+) Acute Myeloid Leukemia.
Lee JW; Kim S; Jang PS; Chung NG; Cho B; Im SA; Kim M
J Pediatr Hematol Oncol; 2020 Apr; 42(3):e132-e139. PubMed ID: 31688618
[TBL] [Abstract][Full Text] [Related]
30. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival.
Schnittger S; Kohl TM; Haferlach T; Kern W; Hiddemann W; Spiekermann K; Schoch C
Blood; 2006 Mar; 107(5):1791-9. PubMed ID: 16254134
[TBL] [Abstract][Full Text] [Related]
31. [A favorable clinical course of acute myeloid leukemia with t (6;21;8)(p23;q22;q22)].
Wada A; Doki N; Otsuka Y; Adachi H; Konuma R; Kishida Y; Konishi T; Yamada Y; Nagata A; Nagata R; Marumo A; Noguchi Y; Mukae J; Toya T; Igarashi A; Najima Y; Kobayashi T; Harada H; Harada Y; Sakamaki H; Ohashi K
Rinsho Ketsueki; 2022; 63(2):104-107. PubMed ID: 35264498
[TBL] [Abstract][Full Text] [Related]
32. AML with RUNX1::RUNX1T1 Cooperating two Mutations Relapsed Quickly after Achieving CR.
XinhongYang ; Wu Y; Yang X; Wu X; Chen Y; Zhang R; Zhang Z
Clin Lab; 2024 Mar; 70(3):. PubMed ID: 38469780
[TBL] [Abstract][Full Text] [Related]
33. LPXN, a member of the paxillin superfamily, is fused to RUNX1 in an acute myeloid leukemia patient with a t(11;21)(q12;q22) translocation.
Dai HP; Xue YQ; Zhou JW; Li AP; Wu YF; Pan JL; Wang Y; Zhang J
Genes Chromosomes Cancer; 2009 Dec; 48(12):1027-36. PubMed ID: 19760607
[TBL] [Abstract][Full Text] [Related]
34. RUNX1 mutation associated with clonal evolution in relapsed pediatric acute myeloid leukemia with t(16;21)(p11;q22).
Ismael O; Shimada A; Elmahdi S; Elshazley M; Muramatsu H; Hama A; Takahashi Y; Yamada M; Yamashita Y; Horide K; Kojima S
Int J Hematol; 2014 Feb; 99(2):169-74. PubMed ID: 24374719
[TBL] [Abstract][Full Text] [Related]
35. Gene mutation profile and risk stratification in AML1‑ETO‑positive acute myeloid leukemia based on next‑generation sequencing.
Yu G; Yin C; Wu F; Jiang L; Zheng Z; Xu D; Zhou J; Jiang X; Liu Q; Meng F
Oncol Rep; 2019 Dec; 42(6):2333-2344. PubMed ID: 31638252
[TBL] [Abstract][Full Text] [Related]
36. Morphological characteristics, cytogenetic profile, and outcome of RUNX1-RUNX1T1-positive acute myeloid leukemia: Experience of an Indian tertiary care center.
Gupta R; Yadav S; Parashar Y; Rahman K; Singh MK; Chandra D; Gupta A; Nityanand S
Int J Lab Hematol; 2020 Feb; 42(1):37-45. PubMed ID: 31725954
[TBL] [Abstract][Full Text] [Related]
37. Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML.
Zampini M; Tregnago C; Bisio V; Simula L; Borella G; Manara E; Zanon C; Zonta F; Serafin V; Accordi B; Campello S; Buldini B; Pession A; Locatelli F; Basso G; Pigazzi M
Leukemia; 2018 May; 32(5):1124-1134. PubMed ID: 29472719
[TBL] [Abstract][Full Text] [Related]
38. RUNX1 mutations in acute myeloid leukemia are associated with distinct clinico-pathologic and genetic features.
Gaidzik VI; Teleanu V; Papaemmanuil E; Weber D; Paschka P; Hahn J; Wallrabenstein T; Kolbinger B; Köhne CH; Horst HA; Brossart P; Held G; Kündgen A; Ringhoffer M; Götze K; Rummel M; Gerstung M; Campbell P; Kraus JM; Kestler HA; Thol F; Heuser M; Schlegelberger B; Ganser A; Bullinger L; Schlenk RF; Döhner K; Döhner H
Leukemia; 2016 Nov; 30(11):2160-2168. PubMed ID: 27137476
[TBL] [Abstract][Full Text] [Related]
39. High aldehyde dehydrogenase activity at diagnosis predicts relapse in patients with t(8;21) acute myeloid leukemia.
Yang L; Chen WM; Dao FT; Zhang YH; Wang YZ; Chang Y; Liu YR; Jiang Q; Zhang XH; Liu KY; Huang XJ; Qin YZ
Cancer Med; 2019 Sep; 8(12):5459-5467. PubMed ID: 31364309
[TBL] [Abstract][Full Text] [Related]
40. AML1-ETO needs a partner: new insights into the pathogenesis of t(8;21) leukemia.
Kuchenbauer F; Feuring-Buske M; Buske C
Cell Cycle; 2005 Dec; 4(12):1716-8. PubMed ID: 16294039
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
